Jacquelyn A. Hank

5.7k total citations
125 papers, 4.3k citations indexed

About

Jacquelyn A. Hank is a scholar working on Immunology, Oncology and Neurology. According to data from OpenAlex, Jacquelyn A. Hank has authored 125 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Immunology, 68 papers in Oncology and 39 papers in Neurology. Recurrent topics in Jacquelyn A. Hank's work include Immune Cell Function and Interaction (46 papers), Immunotherapy and Immune Responses (44 papers) and CAR-T cell therapy research (38 papers). Jacquelyn A. Hank is often cited by papers focused on Immune Cell Function and Interaction (46 papers), Immunotherapy and Immune Responses (44 papers) and CAR-T cell therapy research (38 papers). Jacquelyn A. Hank collaborates with scholars based in United States, Canada and Germany. Jacquelyn A. Hank's co-authors include Paul M. Sondel, Jacek Gan, Stephen D. Gillies, Ralph A. Reisfeld, Mark R. Albertini, Fritz H. Bach, Hiroo Inouye, Alexander L. Rakhmilevich, Jeffrey A. Sosman and Jean E. Surfus and has published in prestigious journals such as Nature, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Jacquelyn A. Hank

124 papers receiving 4.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jacquelyn A. Hank United States	37	2.5k	2.1k	1.4k	1.3k	740	125	4.3k
Maurizio Bendandi Italy	41	1.9k 0.8×	1.9k 0.9×	562 0.4×	1.0k 0.8×	578 0.8×	112	4.7k
Horst Dürkop Germany	28	1.7k 0.7×	1.2k 0.6×	311 0.2×	825 0.6×	406 0.5×	58	3.9k
Harald Stein Germany	33	1.1k 0.5×	1.5k 0.7×	317 0.2×	941 0.7×	548 0.7×	53	4.0k
Doriana Fruci Italy	31	1.8k 0.7×	1.3k 0.6×	445 0.3×	1.3k 1.0×	129 0.2×	82	3.3k
Anne J. Novak United States	41	3.2k 1.3×	2.4k 1.2×	182 0.1×	1.2k 0.9×	347 0.5×	142	5.7k
Claudia Rössig Germany	35	2.4k 1.0×	4.4k 2.1×	632 0.5×	1.4k 1.1×	161 0.2×	157	5.8k
Javier Briones Spain	35	1.7k 0.7×	1.9k 0.9×	316 0.2×	831 0.7×	192 0.3×	161	4.5k
Fabio Morandi Italy	35	1.9k 0.8×	1.1k 0.5×	571 0.4×	733 0.6×	97 0.1×	94	3.3k
Lydia Visser Netherlands	36	1.6k 0.6×	1.3k 0.6×	167 0.1×	1.0k 0.8×	280 0.4×	130	3.8k
Rudolf Schmits Germany	25	2.7k 1.1×	1.1k 0.5×	97 0.1×	1.4k 1.1×	515 0.7×	52	4.5k

Countries citing papers authored by Jacquelyn A. Hank

Since Specialization

Citations

This map shows the geographic impact of Jacquelyn A. Hank's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacquelyn A. Hank with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacquelyn A. Hank more than expected).

Fields of papers citing papers by Jacquelyn A. Hank

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacquelyn A. Hank. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacquelyn A. Hank. The network helps show where Jacquelyn A. Hank may publish in the future.

Co-authorship network of co-authors of Jacquelyn A. Hank

This figure shows the co-authorship network connecting the top 25 collaborators of Jacquelyn A. Hank. A scholar is included among the top collaborators of Jacquelyn A. Hank based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacquelyn A. Hank. Jacquelyn A. Hank is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yu, Alice L., Andrew L. Gilman, M. Fevzi Özkaynak, et al.. (2021). Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clinical Cancer Research. 27(8). 2179–2189. 132 indexed citations

Carlson, Peter M., Владимир Субботин, Ravi B. Patel, et al.. (2021). Depth of tumor implantation affects response to in situ vaccination in a syngeneic murine melanoma model. Journal for ImmunoTherapy of Cancer. 9(4). e002107–e002107. 14 indexed citations

Pieper, Alexander, Alexander L. Rakhmilevich, Ravi B. Patel, et al.. (2021). Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice. Journal for ImmunoTherapy of Cancer. 9(6). e002715–e002715. 29 indexed citations

Yang, Richard K., Igor B. Kuznetsov, Erik A. Ranheim, et al.. (2020). Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2. Clinical Cancer Research. 26(13). 3296–3306. 17 indexed citations

Erbe, Amy K., Peter M. Carlson, Ashley Stuckwisch, et al.. (2019). Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition. Journal for ImmunoTherapy of Cancer. 7(1). 344–344. 53 indexed citations

Morris, Zachary S., Lauryn R. Werner, Peter M. Carlson, et al.. (2018). Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites. Cancer Immunology Research. 6(7). 825–834. 54 indexed citations

Federico, Sara M., M. Beth McCarville, Barry L. Shulkin, et al.. (2017). A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma. Clinical Cancer Research. 23(21). 6441–6449. 114 indexed citations

Erbe, Amy K., Wei Wang, Jacob L. Goldberg, et al.. (2016). FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 23(9). 2159–2168. 12 indexed citations

Morris, Zachary S., David M. Francis, Lauryn R. Werner, et al.. (2016). In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments. Cancer Research. 76(13). 3929–3941. 119 indexed citations

10.

Albertini, Mark R., Erik A. Ranheim, Cindy Zuleger, et al.. (2016). Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma. Cancer Immunology Immunotherapy. 65(8). 897–907. 14 indexed citations

11.

Hank, Jacquelyn A., et al.. (2014). Rhamnose Glycoconjugates for the Recruitment of Endogenous Anti‐Carbohydrate Antibodies to Tumor Cells. ChemBioChem. 15(10). 1393–1398. 79 indexed citations

12.

Lum, Hillary D., Alexander L. Rakhmilevich, Ilia N. Buhtoiarov, et al.. (2008). Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunology Immunotherapy. 57(12). 1891–1902. 47 indexed citations

13.

Neal, Zane C., Michael Imboden, Alexander L. Rakhmilevich, et al.. (2003). NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy. Cancer Immunology Immunotherapy. 53(1). 41–52. 37 indexed citations

14.

Lindstrom, Mary J., et al.. (1998). Differential quantitative effects of interleukin (IL)-2 and IL-15 on cytotoxic activity and proliferation by lymphocytes from patients receiving in vivo IL-2 therapy.. PubMed. 4(5). 1287–96. 6 indexed citations

15.

Nicolet, Charles M., et al.. (1998). Transcription factor activation in lymphokine activated killer cells and lymphocytes from patients receiving IL-2 immunotherapy. Cancer Immunology Immunotherapy. 46(6). 327–337. 3 indexed citations

16.

Surfus, Jean E., Jacquelyn A. Hank, Egbert Oosterwijk, et al.. (1996). Anti-Renal-Cell Carcinoma Chimeric Antibody G250 Facilitates Antibody-Dependent Cellular Cytotoxicity with In Vitro and In Vivo Interleukin-2-Activated Effectors. Journal of Immunotherapy. 19(3). 184–191. 50 indexed citations

17.

Helfand, Stuart C., Steve A. Soergel, Jaime F. Modiano, Jacquelyn A. Hank, & Paul M. Sondel. (1994). Induction Of Lymphokine-Activated Killer (LAK) Activity in Canine Lymphocytes with Low Dose Human Recombinant InterIeukin-2 in vitro. PubMed. 9(3). 237–244. 25 indexed citations

18.

Kaur, Indreshpal, et al.. (1994). Human Peripheral γδ T Cells Are Stimulated by Daudi Burkitt's Lymphoma and Not by Any Other Burkitt's Lymphoma Tested. Cellular Immunology. 156(1). 54–61. 15 indexed citations

19.

Schiller, Joan H., Jacquelyn A. Hank, Barry E. Storer, et al.. (1993). A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.. PubMed. 53(6). 1286–92. 24 indexed citations

20.

Voss, Stephan D., R J Robb, G Weil-Hillman, et al.. (1990). Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.. The Journal of Experimental Medicine. 172(4). 1101–1114. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact